Study of tissue markers in newly diagnosed nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study looks at tissue samples from people with newly diagnosed nasopharyngeal cancer to find biological markers that might help predict how the disease behaves. By joining, you help researchers learn more about the disease and potentially improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been newly diagnosed with nasopharyngeal cancer (confirmed by a biopsy).
- Your cancer must not have spread to other parts of the body (no distant metastasis).
- You must agree to and sign an informed consent form.
- You cannot be receiving treatment that is only meant to relieve symptoms (palliative care).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of radiation therapy that adjusts in real-time to treat nasopharyngeal cancer. It is for people who have not received prior radiation and have no distant spread of cancer.
This Phase 3 trial tests giving chemotherapy first, then either radiation alone or chemotherapy together with radiation. It aims to improve treatment control for people with newly diagnosed, advanced nasopharyngeal cancer.
This study uses special MRI images (and computer “radiomics” scores) to better understand nasopharyngeal cancer. The goal is to help doctors choose the most appropriate treatment for people with newly diagnosed cancer.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
This study uses advanced testing (multi-omics) to predict if combining chemoradiation with immunotherapy works better for nasopharyngeal cancer that has returned or spread. It aims to find the right treatment for each person.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.